BRIEF published on 06/11/2024 at 09:05, 3 months 8 days ago Medincell Joins Euronext Tech Leaders Index Innovation Tech Sector Investor Visibility Medincell Euronext Tech Leaders
PRESS RELEASE published on 06/11/2024 at 09:00, 3 months 8 days ago Informations privilégiées / Autres communiqués Medincell rejoint l’indice Euronext Tech Leaders, accédant à un vaste écosystème et renforçant sa visibilité auprès d'investisseurs internationaux. La technologie BEPO® innovante de Medincell est reconnue Croissance Innovation Medincell Euronext Tech Leaders BEPO®
PRESS RELEASE published on 06/11/2024 at 09:00, 3 months 8 days ago Inside Information / Other news releases Medincell joins Euronext Tech Leaders, gaining access to a broad investor base and support services. CEO Christophe Douat highlights the company's growth and tech innovation leadership Tech Sector Financial Strategy Investor Base Medincell Euronext Tech Leaders
BRIEF published on 05/10/2024 at 18:05, 4 months 9 days ago Medincell announces details on capital and voting rights in accordance with regulations Euronext Paris Share Capital Voting Rights Financial Regulation Medincell
BRIEF published on 05/10/2024 at 18:05, 4 months 9 days ago Medincell annonce les détails sur le capital et les droits de vote conformément à la réglementation Euronext Paris Droits De Vote Réglementation Financière Capital Social Medincell
PRESS RELEASE published on 05/10/2024 at 18:00, 4 months 9 days ago Informations privilégiées / Autres communiqués Annonce mensuelle des actions et droits de vote de Medincell sur Euronext Paris. Medincell développe des médicaments injectables à action prolongée pour divers domaines thérapeutiques Euronext Paris AMF Biopharmaceutique Medincell Médicaments Injectables
BRIEF published on 05/08/2024 at 12:35, 4 months 11 days ago Positive Results for the SOLARIS Phase 3 Trial of Olanzapine Schizophrenia Medincell SOLARIS Olanzapine TEV-'749
BRIEF published on 05/08/2024 at 12:35, 4 months 11 days ago Résultats Positifs pour l'Essai Phase 3 SOLARIS sur l’Olanzapine Schizophrénie Medincell TEV-‘749 SOLARIS Olanzapine
PRESS RELEASE published on 05/08/2024 at 12:30, 4 months 11 days ago Inside Information / Other news releases Teva and Medincell announce positive Phase 3 efficacy results from SOLARIS trial evaluating TEV-'749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia Schizophrenia Medincell Teva Phase 3 Efficacy Results SOLARIS Trial
PRESS RELEASE published on 05/08/2024 at 12:30, 4 months 11 days ago Informations privilégiées / Autres communiqués Les résultats positifs de l'étude de phase 3 SOLARIS démontrent l'efficacité de TV-749, injection sous-cutanée mensuelle pour la schizophrénie par Teva et Medincell Santé Mentale Schizophrénie Medincell TV-749 Teva
Published on 09/20/2024 at 02:00, 2 hours 54 minutes ago Academy of Math and Science Celebrates Hispanic Heritage Month
Published on 09/19/2024 at 23:15, 5 hours 39 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 5 hours 54 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 23:00, 5 hours 54 minutes ago Cerrado Files NI 43-101 Preliminary Economic Assessment Technical Report and Mineral Resource Estimate for The Minera Don Nicolas Mine in Santa Cruz, Argentina
Published on 09/19/2024 at 21:09, 7 hours 44 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 10 hours 9 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 10 hours 51 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 11 hours 1 minute ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 11 hours 1 minute ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 11 hours 9 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 11 hours 9 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 11 hours 9 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)